Tumor Cell Antigens Recognized by Cytotoxic T Lymphocytes (TCAA)

Tumor cell antigens recognized by cytotoxic T lymphocytes (CTLs) are peptide fragments derived from mutated, overexpressed, or uniquely expressed proteins in cancer cells. These peptides are presented on the cell surface in association with MHC class I molecules, allowing CTLs to recognize and kill tumor cells expressing these antigens. These antigens can be tumor-specific (neoantigens), tumor-associated, or derived from viral proteins. Effective anti-tumor immunity relies on the specific recognition of these antigens by CTLs, and immunotherapies aim to enhance this recognition and killing to control tumor growth.

Other names

Tumor-Specific Antigens (TSA)Tumor-Associated Antigens (TAA)NeoantigensMHC-I-presented tumor peptides

Enhancement of T cell recognition and killing of tumor cells expressing specific tumor antigens via TCR-mediated activation. Checkpoint inhibitors enhance T cell activity by blocking inhibitory signals. Adoptive cell therapies introduce engineered or expanded T cells with specificity for tumor antigens. Vaccines aim to prime and boost endogenous T cell responses against tumor antigens.